Ozempic, Wegovy, and Rybelsus are semaglutide-containing drugs from Novo Nordisk. Starting in 2024, there have been reports of non-arteritic anterior ischemic optic neuropathy, or NAION, associated with these semaglutide-containing drugs. And there is new medical evidence in 2026 regarding NAION vision loss with Ozempic, Wegovy, and Rybelsus.
This article, “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes”, published in February 2026 by the medical journal JAMA Ophthalmology, reports on a recent medical study about NAION and semaglutide-containing drugs. The bottom line is that NAION vision loss with Ozempic, Wegovy, and Rybelsus is 2 times higher than, or double, that of some other diabetes drugs, such as Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin), which are sodium-glucose cotransporter-2 (SGLT2) inhibitors, also referred to as SGLT2i drugs.
From the “Key Points” part of that 2026 medical journal article:
Question Is semaglutide associated with an increased risk of incidence of nonarteritic anterior ischemic optic neuropathy (NAION) compared with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes?
Findings In this study, among a group of US veterans with type 2 diabetes, initiation of semaglutide was associated with a 2-fold higher risk of incident NAION compared with initiation of an SGLT2i,…
As of this point in time, the current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about NAION as a possible side effect that can cause vision loss.
Given that situation, together with this new medical evidence in 2026 about NAION vision loss with Ozempic, Wegovy, and Rybelsus, we are handling drug injury lawsuits for patients who have been diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about NAION as a possible side effect.
NAION Vision Loss With Ozempic, Wegovy, and Rybelsus
Here are some of the earlier posts concerning NAION vision loss with Ozempic, Wegovy, and Rybelsus:
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
If you have NAION vision loss with Ozempic, Wegovy, or Rybelsus and are interested in possibly filing a drug injury lawsuit against Novo Nordisk, you can submit an online Case Evaluation Form. If you prefer, send attorney Tom Lamb an email (TJL@LambLawOffice.com) or call him (910-256-2971).
[Read the article in full at Drug Injury Watch]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation